Barclays Maintains Gilead Sciences (GILD) Equal-Weight Recommendation
Fintel reports that on July 11, 2023, Barclays maintained coverage of Gilead Sciences (NASDAQ:GILD) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 23.14% Upside
As of July 6, 2023, the average one-year price target for Gilead Sciences is 93.20. The forecasts range from a low of 77.77 to a high of $120.75. The average price target represents an increase of 23.14% from its latest reported closing price of 75.69.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Gilead Sciences is 26,046MM, a decrease of 3.69%. The projected annual non-GAAP EPS is 6.89.
What is the Fund Sentiment?
There are 2955 funds or institutions reporting positions in Gilead Sciences.
This is an increase
of
21
owner(s) or 0.72% in the last quarter.
Average portfolio weight of all funds dedicated to GILD is 0.52%,
an increase
of 8.80%.
Total shares owned by institutions increased
in the last three months by 0.47% to 1,242,476K shares.
The put/call ratio of GILD is 0.80, indicating a
bullish
outlook.
What are Other Shareholders Doing?
Capital World Investors holds 76,500K shares representing 6.13% ownership of the company. In it's prior filing, the firm reported owning 68,893K shares, representing an increase of 9.94%. The firm increased its portfolio allocation in GILD by 4.06% over the last quarter.
Capital Research Global Investors holds 58,278K shares representing 4.67% ownership of the company. In it's prior filing, the firm reported owning 54,603K shares, representing an increase of 6.31%. The firm decreased its portfolio allocation in GILD by 2.60% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 38,609K shares representing 3.10% ownership of the company. In it's prior filing, the firm reported owning 38,125K shares, representing an increase of 1.26%. The firm decreased its portfolio allocation in GILD by 9.63% over the last quarter.
Dodge & Cox holds 34,702K shares representing 2.78% ownership of the company. In it's prior filing, the firm reported owning 35,885K shares, representing a decrease of 3.41%. The firm decreased its portfolio allocation in GILD by 7.13% over the last quarter.
AMECX - INCOME FUND OF AMERICA holds 33,735K shares representing 2.70% ownership of the company. In it's prior filing, the firm reported owning 32,377K shares, representing an increase of 4.03%. The firm increased its portfolio allocation in GILD by 3.68% over the last quarter.
Gilead Sciences Background Information
(This description is provided by the company.)
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the Southern United States. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.
Additional reading:
- RCUS / Arcus Biosciences Inc / GILEAD SCIENCES INC - EXHIBIT 99.1 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT THE REPORTING PERSON CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL ARCUS BIOSCIENCES, INC. SECOND AMENDED AND RESTATED COMMON STOCK PURC
- GILEAD SCIENCES, INC. EMPLOYEE STOCK PURCHASE PLAN (as Amended and Restated January 25, 2023) Termination Date: January 25, 2033
- GILEAD SCIENCES, INC. INTERNATIONAL EMPLOYEE STOCK PURCHASE PLAN (as Amended and Restated January 25, 2023) Termination Date: January 25, 2033
- Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants commencing in 2023)
- Form of performance share award agreement - TSR Goals (U.S.) under 2022 Equity Incentive Plan (for grants commencing in 2023)
